case_images: PMC4899403_01
case_images: Fragmented red cell had appeared in the peripheral blood and presented severe hemolytic anemia
case_images: 40064_2016_2312_Fig1_HTML.jpg
case_images: PMC4899403_01_40064_2016_2312_Fig1_HTML.jpg
case_images: Fig1
case_images: Rapid elevation of tumor marker levels (CEA 3.9-23.0, CA15-3 9.0-38.7), as manifested by severe anemia, was noted 14 months later, and fragmented red cells emerged in the peripheral blood (Fig. 1).
case_images: Bone scintigraphy was revealed uptake in the spine, ribs, and pelvis, however, there was no clear exacerbation compared to before MAHA onset
case_images: 40064_2016_2312_Fig2_HTML.jpg
case_images: PMC4899403_01_40064_2016_2312_Fig2_HTML.jpg
case_images: Fig2
case_images: Systemic examination with CT showed no evidence of visceral metastasis, and bone scintigraphy revealed slight inhomogeneous uptake in the spine, ribs, and pelvis (Fig. 2); however, there was no clear exacerbation compared to previous results.
case_images: Transition of Tumor marker was linked with the treatment effect. EC epirubicin + cyclophosphamide, LET letrozole, PTX paclitaxel
case_images: 40064_2016_2312_Fig3_HTML.jpg
case_images: PMC4899403_01_40064_2016_2312_Fig3_HTML.jpg
case_images: Fig3
case_images: Therapeutic course and changes in tumor marker levels, red blood and platelet counts are shown in Figs. 3 and 4.
case_images: Transition of RBC and Plt counts was linked with the treatment effect. But in course of treatment, RBC transfusions were performed quite frequently. RBC red blood cell, Plt platelet
case_images: 40064_2016_2312_Fig4_HTML.jpg
case_images: PMC4899403_01_40064_2016_2312_Fig4_HTML.jpg
case_images: Fig4
case_images: Therapeutic course and changes in tumor marker levels, red blood and platelet counts are shown in Figs. 3 and 4.